不同基因分型晚期非小细胞肺癌患者的预后分析  

Prognostic Analysis of Patients with Advanced Non-small Cell Lung Cancer in Different Genotypes

作　　者：刘平[1] 吴羽华[1] 周立娟[2] 秦娜[1] 张权[1] 张卉[1] 李曦[1] 张新勇[1] 吕嘉林[1] 杨新杰[1] 王敬慧[1] 张树才[1] 

机构地区：[1]首都医科大学附属北京胸科医院,北京市结核病胸部肿瘤研究所肿瘤内科,北京101149 [2]首都医科大学附属北京胸科医院,北京市结核病胸部肿瘤研究所病理科,北京101149

出　　处：《中国肺癌杂志》2017年第11期741-750,共10页Chinese Journal of Lung Cancer

基　　金：首都医科大学基础-临床科研合作基金(No.15JL84)资助~~

摘　　要：背景与目的非小细胞肺癌(non-small cell lung cancer,NSCLC)已由原来的组织分型指导下的治疗转变为基因分型指导治疗的模式,表皮生长因子受体(epidermal growth factor receptor,EGFR)和间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)是肺癌最重要的两个驱动基因。本研究旨在探讨不同基因分型的复发或转移晚期NSCLC患者的临床特点及预后影响因素。方法回顾性分析北京胸科医院2004年7月-2015年12月间553例EGFR和ALK基因状态明确的晚期NSCLC患者的临床资料,采用Cox比例风险回归模型对患者预后的独立影响因素进行分析。结果 553例细胞学或组织学证实的晚期NSCLC患者,EGFR突变患者227例,ALK阳性患者58例,EGFR和ALK双突变患者2例,EGFR和ALK野生型患者266例。227例EGFR突变患者的中位生存期(overall survival,OS)为28.7个月(95%CI:22.160-35.240),体能状态(performance status,PS)评分为0分-1分(HR=4.451;95%CI:2.112-9.382;P<0.001)、接受EGFR-酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)靶向治疗(HR=2.785;95%CI:1.871-4.145;P<0.001)是EGFR突变患者生存的独立影响因素。58例ALK阳性患者的中位OS为15.5个月(95%CI:10.991-20.009),接受克唑替尼靶向治疗(P=0.022)是ALK阳性患者生存的独立影响因素。266例野生型患者的中位OS为12.1个月(95%CI:10.660-13.540),PS评分为0分-1分(HR=2.313;95%CI:1.380-3.877;P=0.001)、接受化疗(HR=1.911;95%CI:1.396-2.616;P<0.001)是野生型患者生存的独立影响因素。结论不同基因型的晚期NSCLC患者的预后差异较大,靶向治疗可改善EGFR突变、ALK阳性患者生存。Background and objective Non-small cell lung cancer（NSCLC） has been transformed from the treatment according to histological type to genotype treatment model. The epidermal growth factor receptor（EGFR） and anaplastic lymphoma kinase（ALK） genes are the most important drivers in lung cancer. The aim of this study is to explore the clinical characteristics and prognostic factors of patients with advanced NSCLC with different genotypes. Methods We retrospectively reviewed the clinical data of 553 advanced NSCLC patients with EGFR mutations and ALK positive who were hospitalized in the Beijing Chest Hospital from July 2004 to December 2015, and the independent prognostic factors of patients were analyzed by Cox proportional hazards regression model. Results The clinical data of 553 patients（227 with EGFR mutations, 58 with ALK positive, 2 with EGFR and ALK co-mutation and 266 with wild-type） with advanced NSCLC were enrolled in this study. The median survival time of 227 patients with EGFR mutations was 28.7 mo（95%CI： 22.160-35.240）, and the performance status（PS） score（0-1）（HR=4.451; 95%CI： 2.112-9.382; P〈0.001） and EGFR-tyrosine kinase inhibitors（TKIs） targeted therapy（HR=2.785; 95%CI： 1.871-4.145; P〈0.001） were the independent prognostic factors for the survival of patients harboring EGFR mutations. The median survival time of 58 patients with ALK positive was 15.5 mo（95%CI： 10.991-20.009）, and treatment with crizotinib（P=0.022） was the independent influence factor for the survival of ALK positive patients. The median survival time of 266 patients with wild-type was 12.1 mo（95%CI： 10.660-13.540）, and the PS score（0-1）（HR=2.313; 95%CI： 1.380-3.877; P=0.001） and treatment with chemotherapy（HR=1.911; 95%CI： 1.396-2.616; P〈0.001） were the independent prognostic factors for the survival of wild-type patients. Conclusion The prognosis of patients with advanced NSCLC is associated with genetic mutation, and targeted therapy has a improveme

关 键 词：肺肿瘤 表皮生长因子受体 间变性淋巴瘤激酶 预后 

分 类 号：R734.2[医药卫生—肿瘤]